Skip to Main content Skip to Navigation
Journal articles

When Therapeutic IgA Antibodies Might Come of Age

Abstract : Background: Extensive efforts have been made in optimizing monoclonal immunoglobulin (Ig)G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti-FcαRI could also represent an exciting avenue toward novel therapeutic strategies. Summary: Here, we underline that IgA is more effective in recruiting neutrophils for tumor cell killing and is potently active against several pathogens, including rotavirus, poliovirus, influenza virus, and SARS-CoV-2. IgA could also be used to modulate excessive immune responses in inflammatory diseases. Furthermore, secretory IgA is emerging as a major regulator of gut microbiota, which impacts intestinal homeostasis and global health as well. As such, IgA could be used to promote a healthy microbiota in a therapeutic setting. Key messages: IgA combines multifaceted functions that can be desirable for immunotherapy.
Document type :
Journal articles
Complete list of metadata
Contributor : Hal Sorbonne Université Gestionnaire Connect in order to contact the contributor
Submitted on : Friday, February 12, 2021 - 11:23:26 AM
Last modification on : Friday, December 3, 2021 - 11:43:02 AM
Long-term archiving on: : Thursday, May 13, 2021 - 6:38:34 PM


Sterlin et Gorochov - 2021 - W...
Files produced by the author(s)



Delphine Sterlin, Guy Gorochov. When Therapeutic IgA Antibodies Might Come of Age. Pharmacology, Karger, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩. ⟨hal-03139698⟩



Les métriques sont temporairement indisponibles